Immunogenicity and Safety of 2 Dose Levels of a Thimerosal-Free Trivalent Seasonal Influenza Vaccine in Children Aged 6-35 Months: A Randomized, Controlled Trial.
about
Randomized controlled ferret study to assess the direct impact of 2008-09 trivalent inactivated influenza vaccine on A(H1N1)pdm09 disease riskImmunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6-35 Months of Age During 2013-2014: Results From A Phase II Randomized Trial.Immunogenicity and safety assessment of a trivalent, inactivated split influenza vaccine in Korean children: Double-blind, randomized, active-controlled multicenter phase III clinical trial.Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012-2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical TrialImmunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in childrenA randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of ageTime to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial.Vaccine approaches conferring cross-protection against influenza viruses.Influenza vaccines: Evaluation of the safety profile.A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries.Summary of the NACI Statement on Seasonal Influenza Vaccine for 2017-2018.
P2860
Q27330166-77786A85-69C4-4A19-912F-53655ABCFDA5Q33609256-FF4CEF07-63F2-4E92-A73B-9E0C338E17AEQ35887773-9B957E58-88E5-4B98-B1E9-45EE4D377145Q36009631-84189336-83A3-4CEB-9054-89A043E60558Q37037095-9A0FD404-6FE2-431F-999F-6A456245A961Q37530395-B24CAC43-B818-430D-840E-F17B41C1C08BQ40073913-34F5D4CD-0673-4ED0-952E-5789C11F179DQ41934895-8425F3D9-A3C5-4F97-AC26-874DFD8AE57DQ49345779-92175222-A97C-417E-B77C-F0FBD68D516BQ54626497-B363843D-77FE-4EEF-89AD-5E43FDBFCB7DQ54958007-34F047BE-AACA-4C37-9A5D-E15A2981648F
P2860
Immunogenicity and Safety of 2 Dose Levels of a Thimerosal-Free Trivalent Seasonal Influenza Vaccine in Children Aged 6-35 Months: A Randomized, Controlled Trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Immunogenicity and Safety of 2 ...... Randomized, Controlled Trial.
@en
type
label
Immunogenicity and Safety of 2 ...... Randomized, Controlled Trial.
@en
prefLabel
Immunogenicity and Safety of 2 ...... Randomized, Controlled Trial.
@en
P2093
P2860
P356
P1476
Immunogenicity and Safety of 2 ...... Randomized, Controlled Trial.
@en
P2093
Hartley A Garfield
Jacques Hebert
Louis Fries
Otto G Vanderkooi
Varsha K Jain
Vijayalakshmi Chandrasekaran
P2860
P356
10.1093/JPIDS/PIS012
P577
2012-03-01T00:00:00Z